Literature DB >> 20595802

Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

F Ceccato1, G Occhi, N M Albiger, S Rizzati, S Ferasin, G Trivellin, F Mantero, C Scaroni.   

Abstract

BACKGROUND: Adrenal lesions are discovered in acromegaly more frequently than in general population, without relationship with primary disease. Some patients, carriers of aryl hydrocarbon receptor interacting protein (AIP) gene mutations, developed an adrenal neoplasm. AIM: To evaluate the role of metabolic and genetic aspects and the follow-up of adrenal nodules in acromegaly.
MATERIAL AND METHODS: We studied 69 acromegalic patients (30 male and 39 female, 56 ± 15 yr) who had been referred to the Endocrinology Unit of Padua. In all patients we determined body mass index (BMI) and waist-to-hip ratio (WHR); we performed an oral glucose tolerance test (OGTT) whenever possible. If adrenal computed tomography revealed a lesion, the patient underwent an endocrine and genetic study.
RESULTS: Adrenal lesions were identified in 14 patients and were not related to gender, duration of disease, GH or IGF-I concentrations, basal and after-OGTT glucose and insulin levels, log(HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI) values, whereas BMI and WHR were higher in patients with adrenal lesions. Baseline endocrine and radiological study revealed benign lesions; during mean 4-yr follow-up none of the patients showed hormone excess, even though some lesions increased in size. We did not find any mutation in AIP gene, except heterozygous silent alteration (T48T).
CONCLUSIONS: The frequency of non-functioning adrenal lesions in acromegaly is not associated with the considered aspects, except BMI and WHR. The prolonged follow-up showed that these lesions have a tendency to increase in size independently of the control of acromegaly, so a morphological follow- up is recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20595802     DOI: 10.1007/BF03347459

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  49 in total

1.  Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model.

Authors:  Hui Chen; Gail Sullivan; Michael J Quon
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

Review 2.  Does growth hormone cause cancer?

Authors:  P J Jenkins; A Mukherjee; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2006-02       Impact factor: 3.478

Review 3.  The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences.

Authors:  Sarah de Ferranti; Dariush Mozaffarian
Journal:  Clin Chem       Date:  2008-04-24       Impact factor: 8.327

Review 4.  Adrenal incidentalomas.

Authors:  Jérôme Bertherat; Helen Mosnier-Pudar; Xavier Bertagna
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

5.  Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates.

Authors:  L Barzon; C Scaroni; N Sonino; F Fallo; M Gregianin; C Macrì; M Boscaro
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

Review 6.  Adrenal incidentaloma: evaluation and management.

Authors:  P K Singh; H N Buch
Journal:  J Clin Pathol       Date:  2008-11       Impact factor: 3.411

7.  No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia.

Authors:  A Raitila; M Georgitsi; A Karhu; K Tuppurainen; M J Mäkinen; K Birkenkamp-Demtröder; K Salmenkivi; T F Orntoft; J Arola; V Launonen; P Vahteristo; L A Aaltonen
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

Review 8.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

9.  The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients.

Authors:  Annamaria Colao; Rosario Pivonello; Renata S Auriemma; Mariano Galdiero; Diego Ferone; Francesco Minuto; Paolo Marzullo; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2007-07-24       Impact factor: 5.958

10.  Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas.

Authors:  Laure Cazabat; Rossella Libè; Karine Perlemoine; Fernande René-Corail; Nelly Burnichon; Anne-Paule Gimenez-Roqueplo; Laurence Dupasquier-Fediaevsky; Xavier Bertagna; Eric Clauser; Philippe Chanson; Jérôme Bertherat; Marie-Laure Raffin-Sanson
Journal:  Eur J Endocrinol       Date:  2007-07       Impact factor: 6.664

View more
  3 in total

1.  Does IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?

Authors:  C T Bahadir; G C Ecemis; H Atmaca
Journal:  J Endocrinol Invest       Date:  2018-03-14       Impact factor: 4.256

2.  HOMA-IR in acromegaly: a systematic review and meta-analysis.

Authors:  Betina Biagetti; Anna Aulinas; Anna Casteras; Santiago Pérez-Hoyos; Rafael Simó
Journal:  Pituitary       Date:  2020-10-21       Impact factor: 4.107

3.  AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up.

Authors:  Caterina Mian; Filippo Ceccato; Susi Barollo; Sara Watutantrige-Fernando; Nora Albiger; Daniela Regazzo; Paola de Lazzari; Gianmaria Pennelli; Sandra Rotondi; Davide Nacamulli; Maria Rosa Pelizzo; Marie-Lise Jaffrain-Rea; Franco Grimaldi; Gianluca Occhi; Carla Scaroni
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.